AAP
UTHR icon

Arax Advisory Partners’s United Therapeutics UTHR Stock Holding History

Arax Advisory Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.37M Buy
6,216
+5,535
+813% +$3.12M 0.02% 620
2026
Q1 		$402K Buy
681
+104
+18% +$51.8K 0.01% 738
2025
Q4 		$281K Sell
577
-4,814
-89% -$2.24M 0.01% 864
2025
Q3 		$2.26M Buy
5,391
+5,201
+2,737% +$1.75M 0.03% 433
2025
Q2 		$54.6K Buy
190
+42
+28% +$12.6K ﹤0.01% 1193
2025
Q1 		$45.6K Sell
148
-284
-66% -$97.3K ﹤0.01% 980
2024
Q4 		$152K Sell
432
-32
-7% -$11.8K 0.01% 555
2024
Q3 		$166K Buy
464
+4
+0.9% +$1.35K 0.01% 383
2024
Q2 		$147K Buy
460
+437
+1,900% +$116K 0.01% 393
2024
Q1 		$5.28K Hold
23
– – ﹤0.01% 888
2023
Q4 		$5.06K Buy
23
+3
+15% +$691 ﹤0.01% 884
2023
Q3 		$4.52K Sell
20
-5
-20% -$1.15K ﹤0.01% 897
2023
Q2 		$5.52K Hold
25
– – ﹤0.01% 846
2023
Q1 		$5.6K Hold
25
– – ﹤0.01% 815
2022
Q4 		$6.95K Hold
25
– – ﹤0.01% 708
2022
Q3 		$5K Buy
25
+5
+25% +$1.12K ﹤0.01% 827
2022
Q2 		$5K Buy
+20
New +$4.07K ﹤0.01% 802

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Arax Advisory Partners's UTHR Position: Q2 2026 in Review

Arax Advisory Partners increased its United Therapeutics (UTHR) stake by 813% in Q2 2026, buying an estimated $3.12M and bringing the position to 6,216 shares worth $3.37M. The position accounts for 0.02% of the portfolio, ranked #620.

Arax Advisory Partners first reported a position in UTHR in Q2 2022 and has held it in 17 quarters since. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Arax Advisory Partners held 6,216 shares of United Therapeutics worth $3.37M as of Q2 2026.
  • Arax Advisory Partners bought 5,535 United Therapeutics shares in Q2 2026, an estimated $3.12M.
  • United Therapeutics made up 0.02% of Arax Advisory Partners's portfolio in Q2 2026, its #620 holding.
  • Arax Advisory Partners first reported a position in United Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.